Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.
Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback